- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
PDE4 Inhibitor Roflumilast for AD
Key Takeaways
- The evolution of atopic dermatitis treatments emphasizes nonsteroidal options, reducing corticosteroid dependency and targeting specific inflammatory pathways.
- Nonsteroidal treatments, like PDE4 inhibitors, offer effective modulation of immune responses with a favorable side effect profile.
Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.
Video Player is loading.
- Can you provide an overview of the current landscape of topical treatments for atopic dermatitis and how these options, specifically nonsteroidal options, have evolved over the past decade?
- What is the mechanism of action of PDE4 inhibitors, and how do they specifically target the inflammatory pathways in atopic dermatitis?
Related Videos
Balancing Effective AD Symptom Control with Long-Term Safety in New Therapies
Key Considerations for Evaluating Ruxolitinib Cream as a Treatment for Young Children
Supporting Caregivers in Successful Long-Term Atopic Dermatitis Management: The Role of Dermatologists
Challenges and Emerging Solutions in Treatment for Age Groups: Addressing Disease Control, Safety, and Usability
Challenges and Unmet Needs in Treating Pediatric Atopic Dermatitis
New Biomarker Test Revolutionizes Inflammatory Skin Disease Diagnosis
Reviewing 3 Key Lebrikizumab Abstracts From AAD 2025
Future Directions for Pediatric Atopic Dermatitis Management and Research
New Systemic Therapies for Pediatric Atopic Dermatitis: Nemolizumab and Oral JAK Inhibitors
Addressing Disparities in Inflammatory Skin Diseases in Darker Skin Tones
Related Content
